Clinical Trial Update: Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) [Phase 1]

View source ↗

Summary

A phase 1 trial evaluated the drug-drug interaction between BMS-708163 and galantamine ER and its effect on pharmacokinetics in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BMS-708163
• Galantamine ER (galantamine)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED